What is the current valuation of the Drug Delivery Devices Market?

The Drug Delivery Devices Market was valued at 276.84 USD Billion in 2024. Read More

What is the projected market size for the Drug Delivery Devices Market by 2035?

The market is projected to reach 468.65 USD Billion by 2035. Read More

What is the expected CAGR for the Drug Delivery Devices Market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 4.9%. Read More

Which companies are considered key players in the Drug Delivery Devices Market?

Key players include AbbVie, Becton Dickinson and Company, Medtronic, Johnson & Johnson, Roche, Novartis, Stryker Corporation, Baxter International, and GlaxoSmithKline. Read More

What are the major segments of the Drug Delivery Devices Market?

Major segments include Drug Delivery Route, Device Type, Application, and End User. Read More

How did the Oral drug delivery segment perform in 2024?

The Oral drug delivery segment was valued at 69.0 USD Billion in 2024 and is projected to grow to 115.0 USD Billion by 2035. Read More

What is the market size for Injectable drug delivery devices?

The Injectable segment was valued at 85.0 USD Billion in 2024 and is expected to reach 140.0 USD Billion by 2035. Read More

What is the projected growth for the Cancer application segment?

The Cancer application segment was valued at 70.0 USD Billion in 2024 and is anticipated to grow to 120.0 USD Billion by 2035. Read More

Which end user segment is expected to have the highest valuation by 2035?

The Hospitals end user segment is projected to reach 130.0 USD Billion by 2035. Read More

What is the expected growth for the Nebulizers device type segment?

The Nebulizers segment was valued at 46.84 USD Billion in 2024 and is expected to grow to 78.65 USD Billion by 2035. Read More

Drug Delivery Devices Market

Drug Delivery Devices Market Research Report: Size, Share, Trend Analysis By Drug Delivery Route (Oral, Injectable, Transdermal, Inhalation, Implantable), By Device Type (Syringes, Pumps, Inhalers, Patch Delivery Systems, Nebulizers), By Applications (Diabetes, Cancer, Cardiovascular, Autoimmune Disorders, Pain Management), By End Users (Hospitals, Homecare, Pharmaceutical Companies, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.9%

2024 Market Size

$ 276.84 Billion

2035 Market Size

$ 468.65 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/10320-HCR | Pages: 128 | Author: Vikita Thakur, Kinjoll Dey

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Drug Delivery Route (USD Billion) | |
  1. 4.1.1 Oral | |
  2. 4.1.2 Injectable | |
  3. 4.1.3 Transdermal | |
  4. 4.1.4 Inhalation | |
  5. 4.1.5 Implantable |
2. 4.2 Healthcare, BY Device Type (USD Billion) | |
  1. 4.2.1 Syringes | |
  2. 4.2.2 Pumps | |
  3. 4.2.3 Inhalers | |
  4. 4.2.4 Patch Delivery Systems | |
  5. 4.2.5 Nebulizers |
3. 4.3 Healthcare, BY Application (USD Billion) | |
  1. 4.3.1 Diabetes | |
  2. 4.3.2 Cancer | |
  3. 4.3.3 Cardiovascular | |
  4. 4.3.4 Autoimmune Disorders | |
  5. 4.3.5 Pain Management |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Homecare | |
  3. 4.4.3 Pharmaceutical Companies | |
  4. 4.4.4 Research Institutions |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Becton Dickinson and Company (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Medtronic (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Roche (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Novartis (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Stryker Corporation (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Baxter International (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 GlaxoSmithKline (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
7. 6.4 US MARKET ANALYSIS BY DEVICE TYPE |
8. 6.5 US MARKET ANALYSIS BY APPLICATION |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 CANADA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
11. 6.8 CANADA MARKET ANALYSIS BY DEVICE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY APPLICATION |
13. 6.10 CANADA MARKET ANALYSIS BY END USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
16. 6.13 GERMANY MARKET ANALYSIS BY DEVICE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
19. 6.16 UK MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
20. 6.17 UK MARKET ANALYSIS BY DEVICE TYPE |
21. 6.18 UK MARKET ANALYSIS BY APPLICATION |
22. 6.19 UK MARKET ANALYSIS BY END USER |
23. 6.20 FRANCE MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
24. 6.21 FRANCE MARKET ANALYSIS BY DEVICE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION |
26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DEVICE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
31. 6.28 ITALY MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
32. 6.29 ITALY MARKET ANALYSIS BY DEVICE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY APPLICATION |
34. 6.31 ITALY MARKET ANALYSIS BY END USER |
35. 6.32 SPAIN MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
36. 6.33 SPAIN MARKET ANALYSIS BY DEVICE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION |
38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DEVICE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
45. 6.42 CHINA MARKET ANALYSIS BY DEVICE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY APPLICATION |
47. 6.44 CHINA MARKET ANALYSIS BY END USER |
48. 6.45 INDIA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
49. 6.46 INDIA MARKET ANALYSIS BY DEVICE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY APPLICATION |
51. 6.48 INDIA MARKET ANALYSIS BY END USER |
52. 6.49 JAPAN MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
53. 6.50 JAPAN MARKET ANALYSIS BY DEVICE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION |
55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DEVICE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DEVICE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
64. 6.61 THAILAND MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
65. 6.62 THAILAND MARKET ANALYSIS BY DEVICE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION |
67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DEVICE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DEVICE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DEVICE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
81. 6.78 MEXICO MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
82. 6.79 MEXICO MARKET ANALYSIS BY DEVICE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION |
84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DEVICE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEVICE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DEVICE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DEVICE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG DELIVERY ROUTE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DEVICE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY DRUG DELIVERY ROUTE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY DRUG DELIVERY ROUTE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DRUG DELIVERY ROUTE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DEVICE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Drug Delivery Devices Market Segmentation

Drug Delivery Devices Market By Drug Delivery Route (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Inhalation
Implantable

Drug Delivery Devices Market By Device Type (USD Billion, 2025-2035)

Syringes
Pumps
Inhalers
Patch Delivery Systems
Nebulizers

Drug Delivery Devices Market By Application (USD Billion, 2025-2035)

Diabetes
Cancer
Cardiovascular
Autoimmune Disorders
Pain Management

Drug Delivery Devices Market By End User (USD Billion, 2025-2035)

Hospitals
Homecare
Drug Delivery Devices Market Companies
Research Institutions

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”